Prenetics Global 10/6/2025 Earnings Report

Prenetics Global EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.71
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Prenetics Global Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $21.70 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Prenetics Global Announcement Details

• Date: 10/6/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Prenetics Global (NASDAQ:PRE) (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America. Its consumer brand, CircleDNA, offers a direct-to-consumer genetic testing kit that reports on wellness traits, nutrition, fitness and inherited disease risks. On the corporate side, the company partners with healthcare providers, sports organizations and governments to deploy large-scale testing programs and personalized health initiatives. Prenetics also supports telehealth services, enabling remote consultations based on genetic and diagnostic results.

Founded in 2014 and headquartered in Hong Kong, Prenetics was established by CEO Danny Yeung, a tech entrepreneur with a background in fintech and digital platforms. Under his leadership, the company has expanded through strategic partnerships and investments in laboratory automation and data analytics. Prenetics completed a public listing on the Nasdaq in 2022, positioning itself to accelerate global market expansion and further develop its precision health offerings.